title: Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction.
abstract: The prototypic receptor for IgA (FcalphaRI, CD89) is expressed on myeloid cells and can trigger phagocytosis, tumor cell lysis, and release of inflammatory mediators. The functions of FcalphaRI and activating receptors for IgG (FcgammaRI and FcgammaRIII) are dependent on the FcR gamma-chain dimer. This study increases our understanding of the molecular basis of the FcalphaRI-FcR gamma-chain transmembrane interaction, which is distinct from that of other activatory FcRs. FcalphaRI is unique in its interaction with the common FcR gamma-chain, because it is based on a positively charged residue at position 209, which associates with a negatively charged amino acid of FcR gamma-chain. We explored the importance of the position of this positive charge within human FcalphaRI for FcR gamma-chain association and FcalphaRI functioning with the use of site-directed mutagenesis. In an FcalphaRI R209L/A213H mutant, which represents a vertical relocation of the positive charge, proximal and distal FcR gamma-chain-dependent functions, such as calcium flux, MAPK phosphorylation, and IL-2 release, were similar to those of wild-type FcalphaRI. A lateral transfer of the positive charge, however, completely abrogated FcR gamma-chain-dependent functions in an FcalphaRI R209L/M210R mutant. By coimmunoprecipitation, we have demonstrated the loss of a physical interaction between FcR gamma-chain and FcalphaRI M210R mutant, thus explaining the loss of FcR gamma-chain-dependent functions. In conclusion, not only the presence of a basic residue in the transmembrane region of FcalphaRI, but also the orientation of FcalphaRI toward the FcR gamma-chain dimer is essential for FcR gamma-chain association. This suggests the involvement of additional amino acids in the FcalphaRI-FcR gamma-chain interaction.
authors.affiliation: Immunotherapy Laboratory, Department of Immunology, University Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands;
authors.forename: Jantine E
authors.initials: JE
authors.lastname: Bakema
authors.forename: Simone
authors.initials: S
authors.lastname: de Haij
authors.forename: Constance F
authors.initials: CF
authors.lastname: den Hartog-Jager
authors.forename: Johanna
authors.initials: J
authors.lastname: Bakker
authors.forename: Gestur
authors.initials: G
authors.lastname: Vidarsson
authors.forename: Marjolein
authors.initials: M
authors.lastname: van Egmond
authors.forename: Jan G J
authors.initials: JG
authors.lastname: van de Winkel
authors.forename: Jeanette H W
authors.initials: JH
authors.lastname: Leusen
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D015703:Antigens, CD / Q000235:genetics* / Q000276:immunology / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D008024:Ligands; D051379:Mice; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics*; D010766:Phosphorylation; D011485:Protein Binding; D011961:Receptors, Fc / Q000235:genetics* / Q000276:immunology / Q000378:metabolism*; D017452:Receptors, IgG / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D016415:Sequence Alignment; D015398:Signal Transduction
chemical_list: D015703:Antigens, CD; C036832:Fc(alpha) receptor; D007376:Interleukin-2; D008024:Ligands; D011961:Receptors, Fc; D017452:Receptors, IgG; D020928:Mitogen-Activated Protein Kinases; D002118:Calcium